Cargando…
Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy
The aim of this study is to evaluate the predictive value of carbohydrate antigen125 (CA125) and carcino embryonic antigen (CEA) expression and its guiding role of choosing chemotherapy regimen in post-operation patients with colorectal carcinoma. The clinical data of all patients, including laborat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220750/ https://www.ncbi.nlm.nih.gov/pubmed/32243362 http://dx.doi.org/10.1097/MD.0000000000019420 |
_version_ | 1783533233938366464 |
---|---|
author | Mao, Jie Du, Peng Yang, Han-teng Hu, Huan Wang, Shi-Yao Wu, Xia Cheng, Zhi-Bin |
author_facet | Mao, Jie Du, Peng Yang, Han-teng Hu, Huan Wang, Shi-Yao Wu, Xia Cheng, Zhi-Bin |
author_sort | Mao, Jie |
collection | PubMed |
description | The aim of this study is to evaluate the predictive value of carbohydrate antigen125 (CA125) and carcino embryonic antigen (CEA) expression and its guiding role of choosing chemotherapy regimen in post-operation patients with colorectal carcinoma. The clinical data of all patients, including laboratory data and pathological data, were collected from the electronic medical records. Kaplan-Meier Log rank test, COX regression model and subgroup analyses were employed to assess the correlation between the expression of CA125 and CEA in patients with colorectal carcinoma and the survival, and the effect on chemotherapy efficacy. Kaplan-Meier showed that CA125 expression is negatively related to the progression-free survival (PFS) of the post-operative patients, Median PFS was 1140 days in the patients with high expression, and Median PFS was 1387 days in the patients with low expression (χ(2) = 4.715, P = .030); CEA expression is also negatively associated with the PFS of the post-operative patients, Median PFS was 1197 days in the patients with high expression, and Median PFS was 1424 days in the patients with low expression (χ(2) = 4.992, P = .025). Subgroup analysis also showed that the patients with normal CA125 and CEA had better prognosis, median PFS was 1505 days, and the patients with CA125 and (or) CEA high expression had poor prognosis and median PFS was 1162 days (χ(2) = 13.346, P = .001), and found that there was no statistical difference in patients with oxaliplatin plus capecitabine (XELOX) and oxaliplatin, 5-fluorouracil and Calcium folinate (FOLFOX) chemotherapy in patients with CA125 and CEA low expression. However, in these patients with CA125 or (and) CEA high expression, the median PFS of patients treated with XELOX was 1082 days, and the median PFS of patients treated with FOLFOX chemotherapy was 1335 (χ(2) = 4.547, P = .033). Expression of CA125 and CEA associated with the survival of patients, and have some guiding significance for chemotherapy in patients with colorectal cancer after operation; Compared with XELOX, FOLFOX chemotherapy is more effective for CA125 or (and) CEA high expression patients with colorectal carcinoma. |
format | Online Article Text |
id | pubmed-7220750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-72207502020-06-15 Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy Mao, Jie Du, Peng Yang, Han-teng Hu, Huan Wang, Shi-Yao Wu, Xia Cheng, Zhi-Bin Medicine (Baltimore) 5700 The aim of this study is to evaluate the predictive value of carbohydrate antigen125 (CA125) and carcino embryonic antigen (CEA) expression and its guiding role of choosing chemotherapy regimen in post-operation patients with colorectal carcinoma. The clinical data of all patients, including laboratory data and pathological data, were collected from the electronic medical records. Kaplan-Meier Log rank test, COX regression model and subgroup analyses were employed to assess the correlation between the expression of CA125 and CEA in patients with colorectal carcinoma and the survival, and the effect on chemotherapy efficacy. Kaplan-Meier showed that CA125 expression is negatively related to the progression-free survival (PFS) of the post-operative patients, Median PFS was 1140 days in the patients with high expression, and Median PFS was 1387 days in the patients with low expression (χ(2) = 4.715, P = .030); CEA expression is also negatively associated with the PFS of the post-operative patients, Median PFS was 1197 days in the patients with high expression, and Median PFS was 1424 days in the patients with low expression (χ(2) = 4.992, P = .025). Subgroup analysis also showed that the patients with normal CA125 and CEA had better prognosis, median PFS was 1505 days, and the patients with CA125 and (or) CEA high expression had poor prognosis and median PFS was 1162 days (χ(2) = 13.346, P = .001), and found that there was no statistical difference in patients with oxaliplatin plus capecitabine (XELOX) and oxaliplatin, 5-fluorouracil and Calcium folinate (FOLFOX) chemotherapy in patients with CA125 and CEA low expression. However, in these patients with CA125 or (and) CEA high expression, the median PFS of patients treated with XELOX was 1082 days, and the median PFS of patients treated with FOLFOX chemotherapy was 1335 (χ(2) = 4.547, P = .033). Expression of CA125 and CEA associated with the survival of patients, and have some guiding significance for chemotherapy in patients with colorectal cancer after operation; Compared with XELOX, FOLFOX chemotherapy is more effective for CA125 or (and) CEA high expression patients with colorectal carcinoma. Wolters Kluwer Health 2020-04-03 /pmc/articles/PMC7220750/ /pubmed/32243362 http://dx.doi.org/10.1097/MD.0000000000019420 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 5700 Mao, Jie Du, Peng Yang, Han-teng Hu, Huan Wang, Shi-Yao Wu, Xia Cheng, Zhi-Bin Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy |
title | Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy |
title_full | Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy |
title_fullStr | Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy |
title_full_unstemmed | Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy |
title_short | Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy |
title_sort | prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220750/ https://www.ncbi.nlm.nih.gov/pubmed/32243362 http://dx.doi.org/10.1097/MD.0000000000019420 |
work_keys_str_mv | AT maojie prognosticvalueofcarbohydrateantigen125andcarcinoembryonicantigenexpressioninpatientswithcolorectalcarcinomaanditsguidingsignificanceforchemotherapy AT dupeng prognosticvalueofcarbohydrateantigen125andcarcinoembryonicantigenexpressioninpatientswithcolorectalcarcinomaanditsguidingsignificanceforchemotherapy AT yanghanteng prognosticvalueofcarbohydrateantigen125andcarcinoembryonicantigenexpressioninpatientswithcolorectalcarcinomaanditsguidingsignificanceforchemotherapy AT huhuan prognosticvalueofcarbohydrateantigen125andcarcinoembryonicantigenexpressioninpatientswithcolorectalcarcinomaanditsguidingsignificanceforchemotherapy AT wangshiyao prognosticvalueofcarbohydrateantigen125andcarcinoembryonicantigenexpressioninpatientswithcolorectalcarcinomaanditsguidingsignificanceforchemotherapy AT wuxia prognosticvalueofcarbohydrateantigen125andcarcinoembryonicantigenexpressioninpatientswithcolorectalcarcinomaanditsguidingsignificanceforchemotherapy AT chengzhibin prognosticvalueofcarbohydrateantigen125andcarcinoembryonicantigenexpressioninpatientswithcolorectalcarcinomaanditsguidingsignificanceforchemotherapy |